This article was published on July 10, 2022.
Semaglutide injection (Wegovy™) is a glucagon-like peptide-1 (GLP-1) receptor agonist that is given as a once-weekly subcutaneous injection for “chronic weight management” in specified subgroups of patients (see FDA indications below).
It was approved by the FDA in 2021 and was the first weight-loss medication to be approved since 2014.
On this page, we will provide basic information about this medication. Links to other articles on this website with more advanced information and tips related to this medication and related topics are provided below—under Related Pages below.
Semaglutide injection (Wegovy™) has an FDA indication for “chronic weight management“, what you and I would call weight loss.
But, since it is associated with certain risks, it is not indicated for chronic weight management in everyone who could benefit from losing weight. It is indicated for two groups of people:
1. Those with obesity, defined as a body mass index (BMI) of 30 kg/m2 or more
2. Those with overweight, defined as a body mass index (BMI) of 27 kg/m2 or more … if they also have at least one weight-related comorbid condition (e.g., hypertension, type 2 diabetes mellitus, dyslipidemia).
The FDA indication for semaglutide injection (Wegovy™) has 2 more things to say:
– It is indicated only for adults
– It is indicated for use “as an adjunct to a reduced calorie diet and increased physical activity”.
For more on the use of semaglutide injection (Wegovy™) to treat obestiy and overweight, please see the following article on this website:
Mechanism of Action/ Pharmacodynamics
Semaglutide belongs to a group of medications called glucagon-like peptide-1 (GLP-1) agonists. GLP-1 is involved in the regulation of appetite and food intake.
For more on what GLP-1 is and an overview of other GLP-1 agonists, please see the following article on this website:
Relatively common side effects
In clinical trials, side effects that occurred on semaglutide injection (Wegovy™) with at least a 2% drug-placebo difference were:
All kinds of gastrointestinal side effects can occur (in decreasing order of incidence)—Nausea (28%), vomiting (18%), diarrhea (14%, close to twice as often on medication as on placebo), constipation (13%), abdominal pain (10%), dyspepsia (indigestion; 6%), eructation (belching; 6%), gastritis (2%).
2. Fatigue (6%)
3. Dizziness (4%)
4. Hypoglycemia in patients with type 2 diabetes (4%)
5. Hair loss (3%)
For more about the relatively common side effects of semaglutide injection (Wegovy™), please see the following article on this website:
Other potential serious side effects (Warnings and Precautions)
Semaglutide injection (Wegovy™) comes with the following nine “Warnings and Precautions” (as of July 2022), which are worded exactly as in the official Prescribing Information:
1. Thyroid C-cell tumors (boxed warning)
2. Acute pancreatitis
3. Acute gallbladder disease
5. Acute kidney injury
7. Diabetic retinopathy complications in patients with type 2 diabetes
8. Heart rate increase
9. Suicidal behavior and ideation
10. Delayed gastric emptying
For important points on these ten “Warnings and Precautions” about semaglutide injection (Wegovy™) and what we need to do about them, please see the following article on this website:
Dosage and Administration
The medication dose must be increased gradually over 16 to 20 weeks to 2.4 mg once weekly to reduce gastrointestinal side effects.
Dosage forms and strengths
Wegovy™ is available as a single-use, prefilled syringe in 5 different strengths: 0.25 mg, 0.5 mg, 1 mg, 1.7 mg, and 2.4 mg.
Optional to read: In contrast, Ozembic® is available as prefilled syringes containing 2 mg, 4 mg, or 8 mg of semaglutide. But, these syringes are not for single use. They can be used to deliver specific doses of semaglutide until the medication in that syringe is used up, as follows:
– The syringe containing 2 mg can deliver either 0.25 mg or 0.5 mg at a time
– The syringe containing 4 mg delivers 1 mg at a time
– The syringe containing 8 mg delivers 2 mg at a time.
Important! This page does not provide all the information needed to prescribe this medication. Please refer to the full Prescribing Information (see link below) before prescribing this medication.
Metabolic side effects: General
Does weight gain with second-generation (atypical) antipsychotics plateau after the first few months?
Metabolic side effects: Monitoring
Metabolic side effects: Metformin
Metabolic side effects: Topiramate
Metabolic side effects: Naltrexone/ bupropion
Metabolic side effects: Miscellaneous
Taha MB, Yahya T, Satish P, Laird R, Agatston AS, Cainzos-Achirica M, Patel KV, Nasir K. Glucagon-Like Peptide 1 Receptor Agonists: A Medication for Obesity Management. Curr Atheroscler Rep. 2022 May 28. doi: 10.1007/s11883-022-01041-7. Epub ahead of print. PMID: 35624390.
Copyright © 2022, Simple and Practical Medical Education, LLC. All rights reserved. May not be reproduced in any form without express written permission.
Disclaimer: The content on this website is provided as general education for medical professionals. It is not intended or recommended for patients or other laypersons or as a substitute for medical advice, diagnosis, or treatment. Patients must always consult a qualified health care professional regarding their diagnosis and treatment. Healthcare professionals should always check this website for the most recently updated information.